Abstract
Current treatment of the nephropathy complication of diabetes mellitus is suboptimal in halting the progression of the complex disease. Among the irreversible effects of sustained hyperglycemia is the heightened formation of advanced glycation end products (AGEs). The role of AGEs in diabetic nephropathy has been established by years of basic research. This article reports progression through human studies of the few AGE inhibitors that have reached clinical development, including pimagedine, pyridoxamine, and alagebrium.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Locatelli F, Canaud B, Eckardt KU, et al.: The importance of diabetic nephropathy in current nephrological practice. Nephrol Dial Transplant 2003, 8:716–1725.
Gordois A, Scuffham P, Shearer A, et al.: The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications 2004, 18:18–26.
Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes control and Complications Trial. Diabetes Control and Complications (DCCT) Research Group [no authors listed]. Kidney Int 1995, 47:1703–1720.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977–986.
Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456–1462.
Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315–1321.
Williams ME: New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 2003, 41(3 suppl 1):S42-S47. Concise review of different challenges presented by complex AGE biochemistry, in mainstream nephrology journals.
Caramori ML, Mauer M: Diabetes and nephropathy. Curr Opin Nephrol Hypertens 2003, 12:273–282.
Raj DSC, Choudhury D, Welbourne TC, Levi M: Advanced glycation end-products: a nephrologist’s perspective. Am J Kidney Dis 2000, 35:365–380.
Mene P, Festuccia F, Pugliese F: Clinical potential of advanced glycation end-product inhibitors in diabetes mellitus. Am J Cardiovasc Drugs 2003, 3:315–320.
Rahbar S, Figarola JL: Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003, 419:63–79.
Singh R, Barden A, Mori T, Beilin L: Advanced glycation endproducts: a review. Diabetologia 2001, 44:129–146.
Costantino L, Rastelli G, Gamberini MC, et al.: Pharmacological approaches to the treatment of diabetic complications. Expert Opin Ther Patents 2000, 10:1245–1262.
Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813–819.
Heidland A, Sebekova K, Schinzel R: Advanced glycation end products and progressive course of renal disease. Am J Kidney Dis 2001, 38:S100-S106.
Sabbatini M, Sansone G, Uccello F, et al.: Early glycosylation products induce glomerular hyperfiltration in normal rats. Kidney Int 1992, 42:875–881.
McVerry BA, Hopp AF, Huehns RR: Production of pseudodiabetic renal glomerular changes in mice after repeated injections of glycosylated proteins. Lancet 1980, 2:738–740.
Lee HB, Cha MK, Song KI, et al.: Pathogenic role of advanced glycosylation end products in diabetic nephropathy. Kidney Int 1997, 60:S60-S65.
Sakurai S, Yonekura H, Yamamoto Y: The AGE-RAGE system and diabetic nephropathy. J Am Soc Nephrol 2003, 8:S259-S263.
Forbes JM, Cooper ME, Oldfield MD, et al.: Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003, 14:S254-S258. Recent review of research on the relevance of glycation to the complication of diabetic kidney disease.
Thornalley PJ: Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003, 419:31–40.
Youseff S, Nguyen DJ, Soulis T, et al.: Effects of diabetes and aminoguanidine therapy in renal advanced glycation endproduct binding. Kidney Int 1999, 55:907–916.
Abdel-Rahman E, Bolton WK: Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs 2002, 11:565–574. Updated analysis on the mechanisms and experimental and clinical experience of the prototype AGE inhibitor.
Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes 1992, 41:26–29.
Bolton WK, Cattran DC, Williams ME, et al.: Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004, 24:32–40.
Metz TO, Alderson NL, Thorpe SR, Baynes JW: Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 2003, 419:41–49.
Voziyan PA, Metz TO, Baynes JW, Hudson BG: A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 2002, 277:3397–3403.
Amarnath V, Amarnath K, Amarnath K, et al.: Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls. Chem Res Toxicol 2004, 17:410–415.
Voziyan PA, Khalifah RG, Thibaudeau C, et al.: Modification of proteins in vitro by physiological levels of glucose Pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox meta ions. J Biol Chem 2003, 47:46616–46624.
Onorato JM, Jenkins AJ, Thorpe SR, et al.: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J Bio Chem 2000, 275:21177–21184.
Degenhardt TP, Alderson NL, Arrington DD: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002, 61:939–950.
Alderson NL, Chachich ME, Youssef NY, et al.: The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 2003, 63:2123–2133.
Williams M: A phase 2 clinical trial of Pyridorin in type 1 diabetic patients with overt nephropathy (PYR-206). J Am Soc Nephrol 2003, 14:7A.
McGill JB, Degenhardt TP, Szabo JR, et al.: A phase 2 clinical investigation of pyridoxamine (Pyridorin) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR-205/207) [abstract]. Diabetes 2003, 53:581.
Wassenberg JJ, Knight ST, Fox JW, et al.: The AGE inhibitor pyridoxamine (Pyridorin) reduces urinary TGF-B1 in diabetic patients with overt nephropathy. J Am Soc Nephrol 2003, 14:359A.
Sharma R, Khanna A, Sharma M, Savin VJ: Transforming growth factor Beta-1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int 2000, 58:131–136.
Khalifah RG, Baynes JW, Hudson BG: Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Comm 1999, 257:251–258.
Wolffenbuttel BH, Boulanger CM, Crijns FR, et al.: Breakers of advanced glycation end products restore larger arterial properties in experimental diabetes. Proc Natl Acad Sci U S A 1998, 14:4630–4634.
Candido R, Forbes JM, Thomas MC, et al.: A breaker of advanced glycation end products attenuates diabetic induced myocardial structural changes. Circ Res 2003, 18:785–792.
Susic D, Varagic J, Ahn J, et al.: Crosslink breakers: a new approach to cardiovascular therapy. Curr Opin Cardiol 2004, 19:336–340. Current review in cardiology literature on the emerging field of AGE cross-link breakers and their potential role in cardiovascular disease.
Kass DA, Shapiro EP, Kawaguchi M, et al.: Improved arterial compliance by a novel advanced glycation end product crosslink breaker. Circulation 2001, 25:1464–1470.
Vasan S, Foiles P, Founds H: Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003, 419:89–96.
Cohen MP, Shea E, Chen S, et al.: Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signalregulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med 2003, 141:242–249.
Chen S, Cohen MP, Lautenslager GT, et al.: Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int 2001, 59:673–681.
Amore A, Cirina P, Conti G, et al.: Amadori-configurated albumin induces nitric oxide-dependent apoptosis of endothelial cells: a possible mechanism of diabetic vasculopathy. Nephrol Dial Transplant 2004, 19:53–60.
Cohen MP, Hud E, Shea E, et al.: Normalizing glycated albumin reduces increased urinary collagen IV and prevents renal insufficiency in diabetic db/db mice. Metabolism 2002, 51:901–905.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Williams, M.E. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr Diab Rep 4, 441–446 (2004). https://doi.org/10.1007/s11892-004-0054-0
Issue Date:
DOI: https://doi.org/10.1007/s11892-004-0054-0